Cochrane · systematic review · CD002798
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy
Goh, ET, Andersen, ML, Morgan, MY, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsFlumazenil versus placebo for people with cirrhosis and hepatic encephalopathy
Population: people with hepatic encephalopathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Flumazenil vs placebo | RR 0.75 [0.48, 1.16] | 11 studies · 842 participants | Low Downgraded: risk of bias |
Hepatic encephalopathy Flumazenil vs placebo | RR 0.75 [0.71, 0.8] | 9 studies · 824 participants | Low Downgraded: risk of bias |
Serious adverse events Flumazenil vs placebo | no estimate extracted | 11 studies · 842 participants | Low Downgraded: risk of bias |